Impact of different angiotensin-converting inhibitors on outcomes of post-myocardial infarction patients.

Objective: The aim: To compare the long-term effects of different angiotensin-converting enzyme inhibitors in post-myocardial infarction (MI) patients.

Patients And Methods: Materials and methods: Of 445 consecutive patients with myocardial infarction, 76 (17%) patients had co-morbid conditions, as well as were found to be compliant with secondary prevention treatment and eligible for follow-up. These patients were assigned to ramipril, perindopril or zofenopril groups in complex management of post-MI period.

[THE LOCAL REGISTRY DATA ON MYOCARDIAL INFARCTION IN WOMEN: THE RISK FACTOR ANALYSIS, CLINICAL CHARACTERISTICS AND SURVIVAL].

The clinical experience implies poor prognosis in women with myocardial infarction (MI). We performed a retrospective cohort study of 1395 patients - 987 (70,75%) men and 408 (29,25%) women) aged of 64,63±11,43 years with myocardial infarction and comorbidity hospitalized between 2010-2016. This study shows an increase of mortality in women with myocardial infarction during the last 4 years from 23,1% to 34,2%.

[3',5'-cAMP phosphodiesterase inhibitors in the combined treatment of patients with rheumatoid arthritis].

A study was made of clinical effectiveness and mechanism of action of the inhibitor of the specific 3',5'-cAMP phosphodiesterase papaverine in a therapeutic complex of measures designed to treat RA patients involving an immunodepressive preparation free from any cytopenic effect prospidin as a basic mediator. It has been shown that the papaverine antiarthritic action is associated with its positive effects on the unspecific component of the immune-complex inflammation, viz. processes of lipid peroxidation, activity of the antioxidant system of defence as well as on the vascular tone and microcirculation.